Transgene and BioInvent are co-developing BT-001, an oncolytic virus developed using Transgene’s Invir.IO® platform armed to express GM-CSF and BioInvent’s full-length anti-CTLA-4 monoclonal antibody, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback